Advertisement: Cambridge Network
Advertisement: RSM
Advertisement EY mid banner
Mid banner advertisement: BDO
RealVNC mid-banner general
ARM Innovation Hub
Advertisement: Mogrify
Advertisement: Bradfield Centre mid
RealVNC mid banner careers
Barr Ellison Solicitors – commercial property
9 May, 2018 - 10:16 By Tony Quested

Inivata plunged into search for CEO as Stocum quits

Cambridge cancer genomics business Inivata is looking for a new CEO. The search has been sparked by Michael Stocum’s decision to step down to pursue other interests.

Inivata is a global clinical cancer genomics company utilising what it calls an industry-leading liquid biopsy platform to transform patient care. Stocum said: “It has been a privilege leading Inivata as we grew from an academic spinout to our current stage of development over the past four years. 

“The company is now entering its next stage of growth with an increasing focus on commercialisation and needs a CEO with a different set of skills.” 

Inivata has developed a highly-sensitive liquid biopsy platform that positions it strongly in a fast-growing market. Using a simple blood test (liquid biopsy), the Inivata analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment.

The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge.

It combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. 

Inivata has established collaborations with world-leading cancer centres and academic institutions and is partnering with pharmaceutical and biotechnology companies.

The company has a CLIA lab in Research Triangle Park, North Carolina and laboratories in Cambridge UK.

• PHOTOGRAPH SHOWS: Michael Stocum

Newsletter Subscription

Stay informed of the latest news and features